CHRNA7 have been associated with intellectual disability (ID), seizures and neuropsychiatric phenotypes. Decreased expression of CHRNA7, the gene encoding the alpha7( *) subtype of nicotinic receptor, may contribute to the cognitive dysfunction observed in schizophrenia by disrupting the inhibitory/excitatory balance in the hippocampus. The human alpha7 neuronal nicotinic acetylcholine receptor gene (CHRNA7) is ubiquitously expressed in both the central nervous system and in the periphery. CHRNA7 is genetically linked to multiple disorders with cognitive deficits, including schizophrenia, bipolar disorder, ADHD, epilepsy, Alzheimer's disease, and Rett syndrome. There is a genetic link between CHRNA7 and startle magnitude, indicating that cholinergic neurotransmission involving the alpha7nAChR could be involved in sensory registration processes. The overexpression of CHRNA7 negatively controls colorectal cancer LoVo cell invasion and metastasis via PI3K/Akt pathway activation and may serve as either a diagnostic marker or a therapeutic target for colorectal cancer metastasis.